Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
基本信息
- 批准号:10317075
- 负责人:
- 金额:$ 39.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-01-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAlkenesAlkynesAmino AcidsArrestinsBiologicalBiologyBiophysicsBiosensorCellsChemicalsChemistryComplexCouplingCrosslinkerCysteineDevelopmentDiabetes MellitusDrug TargetingEpidermal Growth Factor ReceptorFluoresceinFluorescenceFluorescence Resonance Energy TransferG-Protein-Coupled ReceptorsGeneticGenetic CodeIn SituLabelLigandsLigationMammalian CellMapsMass Spectrum AnalysisMediatingMolecular Biology TechniquesMolecular ConformationMovementObesityPalladiumPhotoaffinity LabelsProtein ConformationProteinsProteomicsReactionReagentReceptor ActivationReceptor SignalingResearchSignal TransductionSiteTetrazolesThiazolesTimebasechemical functioncyanine dye 5cycloadditiondesignextracellularfluorophoreinsightinterestmembernovelprotein protein interactionreal time monitoringreceptorresponsetargeted treatmenttooltool development
项目摘要
Development and Applications of Bioorthogonal Chemistry
ABSTRACT
This MIRA application combines two research efforts in our lab in tackling the critical barriers in the study of
class B GPCR biophysics and signaling in live cells, i.e., the lack of suitable tools for constructing functional
GPCR biosensors as well as capturing the transient and highly dynamic GPCR-interacting proteins involved in
biased agonism. We have a long-standing interest in developing the reactivity-based chemical tools to address
significant biological problems that are difficult to solve using conventional molecular biology techniques. In the
past five years we continued to make progress in both tool development and the applications of these tools to
address important biological problems. For instance, we optimized several bioorthogonal reactions, including
the photoinduced tetrazolealkene cycloaddition reaction (‘photoclick’ chemistry), the spiroalkenetetrazine
ligation reaction, the palladium-mediated cross-coupling reactions, and the sequence-specific 2-cyanobenzo-
thiazolecysteine ligation reaction. Together with the genetic code expansion involving a spiroalkene amino
acid, two of these reactions (photoclick chemistry and tetrazine ligation) were harnessed for site-specific
introduction of organic fluorophore (fluorescein, Cy3 and Cy5) at the extracellular loop 3 of GLP-1R and GCGR,
two members of the class B GPCRs implicated in diabetes and obesity, for an ongoing single-cell FRET study
of the domain movement during ligand-induced receptor activation in live cells. In addition, we made a
serendipitous discovery that 2-aryl-5-carboxytetrazole (ACT) offers a new proximity-dependent photo-cross-
linker, which was then used in the design of the photo-affinity labels that enabled in situ capture and
subsequent identification of the drug targets as well as a genetically encoded amino acid for site-specific
incorporation and subsequent capture of the transient EGFRGrb2 interaction complex in mammalian cells.
Built upon these results, in this application we plan to continue our studies of orthogonal chemical reactivity at
the chemistry-biology interface and pursue the following two related projects. In Project 1, we will construct the
FRET-based biosensors of GLP-1R and GCGR via bioorthogonal labeling to probe the conformational
dynamics involved in the receptor activation and signaling in live cells. A new set of fluorescence ‘turn-on’
reagents will be designed for bioorthogonal, fluorescent labeling of the intracellular loop 3 (ICL3) of GLP-1R
and GCGR to allow single-cell intra- and intermolecular FRET analysis of receptor conformations in live cells.
In Project 2, we will develop a genetically encoded ACT photo-cross-linker containing an alkyne group and
apply this photo-cross-linker to map the time-dependent GLP-1R and -arrestins interactomes by mass
spectrometry in response to ligand stimulation. We expect that these studies will not only validate new
chemical tools for real-time monitoring of protein conformations and protein-protein interactions in live cells but
also provide novel insights into the GLP-1R and GCGR activation and biased signaling that are crucial for the
development of targeted therapies for the treatment of diabetes and obesity.
生物正交化学的发展与应用
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Qing Lin其他文献
Qing Lin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Qing Lin', 18)}}的其他基金
Development of Orally Administered Peptide Hormones for Treatment of Diabetes and Obesity
用于治疗糖尿病和肥胖症的口服肽激素的开发
- 批准号:
10323876 - 财政年份:2021
- 资助金额:
$ 39.62万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
- 批准号:
10543732 - 财政年份:2019
- 资助金额:
$ 39.62万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry: Administrative Supplement for Equipment
生物正交化学的发展与应用:设备管理补充
- 批准号:
10581256 - 财政年份:2019
- 资助金额:
$ 39.62万 - 项目类别:
Development and Applications of Photoinducible Bioorthogonal Chemistry
光诱导生物正交化学的发展及应用
- 批准号:
8240114 - 财政年份:2009
- 资助金额:
$ 39.62万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
- 批准号:
8913203 - 财政年份:2009
- 资助金额:
$ 39.62万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
- 批准号:
9309042 - 财政年份:2009
- 资助金额:
$ 39.62万 - 项目类别:
Development and Applications of Photoinducible Bioorthogonal Chemistry
光诱导生物正交化学的发展及应用
- 批准号:
8460102 - 财政年份:2009
- 资助金额:
$ 39.62万 - 项目类别:
Development and Applications of Photoinducible Bioorthogonal Chemistry
光诱导生物正交化学的发展及应用
- 批准号:
7793428 - 财政年份:2009
- 资助金额:
$ 39.62万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
- 批准号:
9266090 - 财政年份:2009
- 资助金额:
$ 39.62万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
- 批准号:
8759491 - 财政年份:2009
- 资助金额:
$ 39.62万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 39.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 39.62万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:














{{item.name}}会员




